CJC-1295 is an investigational synthetic analogue of growth hormone-releasing hormone (GHRH). It has been studied for its ability to increase circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although a small early human trial found sustained changes in these hormone markers, those findings do not establish that CJC-1295 improves muscle growth, fat loss, athletic performance, recovery, or longevity (Teichman et al., 2006).
The distinction matters: a measurable change in a hormone is not the same as a proven health benefit. Available clinical evidence is limited, long-term safety is not established, and regulators have raised concerns about products containing CJC-1295. This article summarizes what published evidence and official safety notices say; it is not a guide to using or administering the peptide.
Key takeaways
- CJC-1295 is a long-acting GHRH analogue investigated for its effects on GH and IGF-1.
- A randomized, placebo-controlled study in healthy adults reported increased GH and IGF-1 levels, but it was not evidence of improved muscle, fat-loss, athletic, or anti-aging outcomes (Teichman et al., 2006).
- The human evidence base is small, and long-term benefits and risks remain uncertain.
- The FDA identifies limited clinical data and reports of serious adverse events associated with CJC-1295-containing compounded drugs, including increased heart rate and a systemic vasodilatory reaction (FDA, n.d.).
- Health Canada lists CJC-1295 among unauthorized injectable peptide drugs and advises consumers not to buy or use such products (Health Canada, 2026).
What is CJC-1295?
CJC-1295 is a synthetic analogue designed to act on the growth hormone-releasing hormone pathway. GHRH is a natural signal that binds to receptors on somatotroph cells in the pituitary gland and stimulates GH secretion. CJC-1295 was developed to produce a longer-lasting hormonal response than native GHRH (Teichman et al., 2006).
What does DAC mean?
The term DAC refers to a Drug Affinity Complex modification intended to bind the peptide to circulating albumin and extend its presence in the bloodstream. In the published human study of CJC-1295, the estimated half-life was approximately 5.8–8.1 days, consistent with prolonged activity (Teichman et al., 2006).
Online sellers and discussion forums do not always use names for CJC-1295 variants consistently. Claims about products labelled “no DAC” should not automatically be treated as evidence about the DAC-modified compound studied in the published trial. Product identity and composition can be difficult to verify outside regulated settings.
How CJC-1295 may affect growth hormone and IGF-1
GH is released by the pituitary gland in a regulated, pulsatile pattern. It affects multiple tissues and stimulates production of IGF-1, especially in the liver; IGF-1 also acts locally in tissues. Both hormones are controlled by feedback mechanisms and interact with age, nutrition, sleep, metabolic health, and other physiological factors.
Because CJC-1295 targets the GHRH pathway, researchers have measured changes in GH and IGF-1 as indicators of biological activity. These are surrogate markers: they can show that a compound affects a pathway, but they cannot by themselves demonstrate better health, body composition, physical function, or lifespan.
What has human research found?
Teichman and colleagues published a randomized, double-blind, placebo-controlled study in 2006 involving healthy adults aged 21–61. The research included two ascending-dose trials lasting 28 and 49 days and examined pharmacokinetics, hormone responses, and short-term safety (Teichman et al., 2006).
After a single administration, mean GH concentrations increased in a dose-dependent manner, and mean IGF-1 concentrations also rose for several days. With repeated administrations, IGF-1 remained above baseline for a longer period. No serious adverse reactions were reported in that study. However, the study was relatively small and short, and its main outcomes were hormone measurements rather than clinical benefits.
What the study does not prove
- Muscle growth: Hormone-marker changes do not prove an increase in muscle mass or strength.
- Fat loss: The study did not establish CJC-1295 as an effective weight-management treatment.
- Athletic performance or recovery: The trial did not demonstrate improved competitive performance, injury recovery, or training outcomes.
- Anti-aging or longevity: There is no adequate clinical evidence that CJC-1295 reverses aging or extends human lifespan.
- Long-term safety: A short study in selected healthy adults cannot establish the safety of repeated use over months or years or in people with underlying health conditions.
These limitations are important when interpreting promotional claims. The existence of a human study does not mean a substance has been proven effective for every use promoted online.
Potential risks and safety uncertainties
Safety cannot be inferred from a proposed mechanism or from the absence of serious events in one small trial. The U.S. Food and Drug Administration (FDA) states that available clinical data for CJC-1295 are limited. It also identifies reports of serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes concerns about immunogenicity and peptide-related impurities in compounded products (FDA, n.d.).
Because CJC-1295 affects the GH/IGF-1 axis, altering this pathway may have consequences that depend on the individual and the degree and duration of hormonal change. The current evidence does not adequately define the risks of long-term exposure, repeated use, use in higher-risk populations, or products obtained from unverified sellers. It would be misleading to present a definitive list of side effects or to imply that all risks are known.
Product quality is a separate concern
Products sold online as research chemicals may not have the identity, purity, concentration, sterility, or quality controls expected of authorized medicines. A “research use only” label does not establish that a product is safe for people. FDA notes that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, and quality before marketing (FDA, n.d.).
Regulatory status in Canada and the United States
Canada: Health Canada includes CJC-1295 among unauthorized injectable peptide drugs and advises consumers not to buy or use unauthorized products. The agency states that such products have not been assessed for safety, efficacy, and quality, and that injectable peptides are generally regulated as prescription drugs in Canada (Health Canada, 2026).
United States: The FDA lists CJC-1295 in its discussion of bulk drug substances that may present significant safety risks in compounding. The agency specifically notes limited clinical data and reported serious adverse events (FDA, n.d.). This is not the same as FDA approval of CJC-1295 as a treatment; the compound should not be represented as an FDA-approved medicine for bodybuilding, anti-aging, or general wellness.
Regulatory status can change, so readers should consult the relevant regulator’s current information rather than relying on a seller’s description or an online forum.
What to consider instead
For concerns about low energy, body composition, recovery, or a suspected hormone disorder, a qualified healthcare professional can assess symptoms and determine whether validated testing or an established treatment is appropriate. Treatment decisions should be based on a clinical diagnosis and the balance of demonstrated benefits and known risks—not on an attempt to raise a biomarker in isolation.
If you have used an unauthorized injectable peptide and feel unwell or are concerned about possible effects, contact a healthcare professional. Health Canada specifically advises people not to use unauthorized injectable peptide products and to seek medical advice if they have used them and have concerns (Health Canada, 2026).
Conclusion
CJC-1295 has been studied in humans and shown to produce sustained increases in GH and IGF-1 biomarkers. That is evidence of a biological effect, not proof of benefits for muscle growth, fat loss, athletic performance, recovery, or longevity. The limited size and duration of the available human research leave major questions about clinical effectiveness and long-term safety unanswered.
Official safety information also highlights concerns about serious adverse events and the quality of compounded or unauthorized peptide products. CJC-1295 should not be presented as an established treatment for general wellness or performance enhancement. Anyone considering a hormone-related intervention should discuss the issue with a qualified healthcare professional.
Frequently asked questions
What is CJC-1295?
CJC-1295 is an investigational synthetic analogue of GHRH studied for its ability to stimulate GH and IGF-1. Its effects on these hormone markers do not establish that it improves health or performance.
Does CJC-1295 increase growth hormone and IGF-1?
A randomized, placebo-controlled study in healthy adults reported sustained increases in GH and IGF-1 after CJC-1295 administration (Teichman et al., 2006). The findings were about hormone concentrations, not proof of broader clinical benefits.
Is CJC-1295 proven to build muscle or burn fat?
No. The available human study does not establish CJC-1295 as an effective treatment for muscle growth, fat loss, or athletic performance.
What are the known safety concerns?
The FDA says clinical data are limited and identifies reports of increased heart rate and a systemic vasodilatory reaction associated with CJC-1295, alongside concerns about immunogenicity and peptide impurities in compounded products (FDA, n.d.). The full long-term risk profile is not established.
Is CJC-1295 approved in Canada?
Health Canada lists CJC-1295 among unauthorized injectable peptide drugs and advises consumers not to buy or use unauthorized products (Health Canada, 2026). Check current official sources for the latest regulatory information.
Does “research use only” mean a product is safe?
No. That wording does not establish safety, quality, or authorization for human use. Products from unverified sources may have uncertain identity, purity, concentration, or sterility.
References
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- U.S. Food and Drug Administration. (n.d.). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA official page
- U.S. Food and Drug Administration. (n.d.). Understanding the risks of compounded drugs. FDA official page
- Health Canada. (2026, April 9). Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Health Canada advisory
- Health Canada. (n.d.). Using bodybuilding products. Health Canada guidance
Editorial note: This article is for general educational purposes and is not medical advice. It does not recommend use, dosing, or administration of CJC-1295.
